Celldex Therapeutics, Inc.
CLDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $1 | $1 |
| % Growth | -100% | 5% | -40.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $0 | $1 | $1 | $0 |
| % Margin | – | 100% | 100% | 30.3% |
| R&D Expenses | $63 | $54 | $53 | $46 |
| G&A Expenses | $11 | $10 | $11 | $10 |
| SG&A Expenses | $11 | $10 | $11 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $74 | $65 | $63 | $56 |
| Operating Income | -$74 | -$64 | -$63 | -$56 |
| % Margin | – | -8,747.5% | -9,027.2% | -4,768.3% |
| Other Income/Exp. Net | $7 | $7 | $9 | $9 |
| Pre-Tax Income | -$67 | -$57 | -$54 | -$47 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$67 | -$57 | -$54 | -$47 |
| % Margin | – | -7,753.4% | -7,740.4% | -4,007.8% |
| EPS | -1.01 | -0.85 | -0.81 | -0.71 |
| % Growth | -18.8% | -4.9% | -14.1% | – |
| EPS Diluted | -1.01 | -0.85 | -0.81 | -0.71 |
| Weighted Avg Shares Out | 66 | 66 | 66 | 66 |
| Weighted Avg Shares Out Dil | 66 | 66 | 66 | 66 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $7 | $9 | $9 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$66 | -$63 | -$62 | -$55 |
| % Margin | – | -8,627.9% | -8,902.4% | -4,698.6% |